Greta Gerwig’s ‘Narnia’ Moves to 2027 With Global Theatrical Release Before Netflix Debut

Greta Gerwig’s "Narnia: The Magician’s Nephew" is now set for a Feb. 12, 2027 theatrical release, with Netflix debuting the film on April 2, 2027 and Imax sneak previews beginning Feb. 10. The release was delayed from Thanksgiving 2026 to allow for a wider theatrical window. Netflix and Imax continue to back the project, which is a high-profile fantasy adaptation but not material to broader markets.

Analysis

The release shift is more important for IMAX than for Netflix: it converts an initially modest prestige-title event into a measurable premium-format catalyst with a longer sell-through window. A February IMAX-only-ish debut also concentrates attention into a period with fewer competing tentpoles, which should improve per-screen economics and keep IMAX shares’ move anchored to exhibit demand rather than streamer subscriber math.

For NFLX, the key second-order effect is not the film itself but the signaling value: allowing a longer theatrical runway suggests management is still willing to optimize monetization across windows when the title can support it. That is constructive for content ROI discipline, but it also subtly acknowledges that some high-end IP is better harvested as an event first, which could temper the market’s assumption that all premium content is strategically “streamer-native.”

The more interesting read-through is competitive, not binary. Disney and other family/franchise studios should view this as validation that appointment viewing still matters for tentpole fantasy, especially when prestige creative can justify a premium launch and later streaming tail. The risk is execution: if the film underperforms in theaters, the extended window amplifies the gap between expectations and actual demand, so the first 4-6 weeks of sales data will matter more than the release date itself.

Contrarian angle: consensus will likely treat this as mildly bullish for both NFLX and IMAX and stop there. The larger opportunity may be in IMAX relative outperformance if the title proves culturally sticky, because a successful family-event franchise can create repeat-format behavior that extends beyond this single release; conversely, if broader box office weakens into 2027, the benefit to NFLX could be muted because the title’s value becomes more about brand halo than direct subscriber impact.

Key Decisions for Investors

• Long IMAX vs. short a basket of megacap media/streaming names into the first trailer-marketing cycle; the setup favors IMAX on the path to release because premium-format scarcity can drive asymmetric near-term upside.
• Add a tactical long in NFLX only on weakness, not strength; treat this as a sentiment-positive IP monetization signal with limited direct EPS impact, and use a 3-6 month horizon rather than chasing a one-day move.
• Buy IMAX call spreads dated through March 2027 to capture release-window and early-preview demand; risk/reward improves if advance sales show family-audience elasticity similar to prior event films.
• Use the date shift to fade near-term overreaction in DIS-linked franchise sentiment; this is not a Disney-demand shock, so any sympathy bid in legacy studio names looks like a short-duration trading opportunity rather than a structural rerate.